Application and Prospect of Circulating Tumor DNA Detection in the Management of Postoperative Molecular Residual Lesions of Colorectal Cancer

Jingyu Gong

doi:10.47297/wspbdsWSP2752-630523.20260601

PDF
导出
分享
收藏
专辑

Application and Prospect of Circulating Tumor DNA Detection in the Management of Postoperative Molecular Residual Lesions of Colorectal Cancer

6卷第1期

浏览量: 0 Downloads: 0

Application and Prospect of Circulating Tumor DNA Detection in the Management of Postoperative Molecular Residual Lesions of Colorectal Cancer
Application and Prospect of Circulating Tumor DNA Detection in the Management of Postoperative Molecular Residual Lesions of Colorectal Cancer
Shandong Medical And Pharmaceutical University, Yantai, Shandong, 264003, China
2026年6卷第1期页码：102-105
纸质出版：2026-03-30
DOI：10.47297/wspbdsWSP2752-630523.20260601
Accepted：

Scan QR Code

Jingyu Gong. (2026). Application and Prospect of Circulating Tumor DNA Detection in the Management of Postoperative Molecular Residual Lesions of Colorectal Cancer. 生物医学大数据, 6(1), 102-105.

Gong Jingyu.Application and Prospect of Circulating Tumor DNA Detection in the Management of Postoperative Molecular Residual Lesions of Colorectal Cancer[J].Biomedical Data Science,2026,06(01):102-105.
Jingyu Gong. (2026). Application and Prospect of Circulating Tumor DNA Detection in the Management of Postoperative Molecular Residual Lesions of Colorectal Cancer. 生物医学大数据, 6(1), 102-105. DOI： 10.47297/wspbdsWSP2752-630523.20260601.

Gong Jingyu.Application and Prospect of Circulating Tumor DNA Detection in the Management of Postoperative Molecular Residual Lesions of Colorectal Cancer[J].Biomedical Data Science,2026,06(01):102-105. DOI： 10.47297/wspbdsWSP2752-630523.20260601.

摘要

Abstract

Advances in circulating tumor DNA (ctDNA) detection technology have provided a transformative tool for the monitoring and intervention of molecular residual disease (MRD) after radical resection of colorectal cancer. CtDNA are reviewed in this paper

system - the two technical path of MRD detection: individualized customization strategy with fixed Panel

and compared its performance characteristics and applicable scenario. This article focuses on the excellent prognostic value of ctDNA in postoperative risk stratification

which is significantly more effective than traditional clinicopathological indicators

and can effectively identify people with high risk of recurrence that cannot be identified by traditional staging. In addition

this article summarizes the breakthrough clinical evidence for ctDNA status to guide the decision of "upgrading and downgrading" of adjuvant therapy

and reveals its potential to promote individualized precision treatment. Although facing technology standardization

cloned hematopoietic interference and economic cost challenges

but through technology innovation

prospective clinical verification and ecology system builds

ctDNA - MRD detection is expected to completely change the postoperative management of colorectal cancer model

lead the patient into the molecular dynamic precise management under the guidance of the new age.

关键词

Keywords

references

Pantel K , Alix-Panabieres C . Minimal residual disease as a target for liquid biopsy in patients with solid tumours . Nat Rev Clin Oncol . 2025 ; 22 ( 1 ) : 65 - 77 .

Boukovala M , Westphalen CB , Probst V . Liquid biopsy into the clinics: Current evidence and future perspectives . J Liq Biopsy . 2024 ; 4 : 100146 . Published 2024 Feb 11.

El-Hussuna A , Lytras T , Bruun NH , Klein MF , Emile SH , Qvist N . Extended Right-Sided Colon Resection Does Not Reduce the Risk of Colon Cancer Local-Regional Recurrence: Nationwide Population-Based Study From Danish Colorectal Cancer Group Database . Dis Colon Rectum . 2023 ; 66 ( 8 ) : 1056 - 1066 .

Martinez-Castedo B , Camblor DG , Martin-Arana J , et al . Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy . Ann Oncol . 2025 ; 36 ( 3 ) : 263 - 276 .

Zhao J , Reuther J , Scozzaro K , et al . Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors . Mol Diagn Ther . 2023 ; 27 ( 6 ) : 753 - 768 .

Frydendahl A , Rasmussen MH , Jensen SØ , et al . Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA . Int J Mol Sci . 2024 ; 25 ( 8 ) : 4252 .

Martin-Arana J , Gimeno-Valiente F , Henriksen TV , et al . Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer . Nat Cancer . 2025 ; Six ( 6 ) : 1000 - 1016 .

Wen X , Coradduzza D , Shen J , et al . Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges . Medicina (Kaunas) . 2023 ; 59 ( 10 ): 1886 . Published 2023 Oct 23.

Nakamura Y , Watanabe J , Akazawa N , et al . ctDNA-based molecular residual disease and survival in resectable colorectal cancer . Nat Med . 2024 ; 30 ( 11 ) : 3272 - 3283 .

Mo S , Ye L , Wang D , et al . Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation . JAMA Oncol . 2023 ; 9 ( 6 ) : 770 - 778 .

Tie J , Wang Y , Lo SN , et al . Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial . Nat Med . 2025 ; 31 ( 5 ) : 1509 - 1518 .

Henriksen TV , Tarazona N , Frydendahl A , et al . Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences . Clin Cancer Res . 2022 ; 28 ( 3 ) : 507 - 517 .

Ando K , Hamabe A , Nakamura Y , et al . Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study . Ann Surg . 2026 ; 283 ( 1 ) : 13 - 21 .

Tie J , Wang Y , Loree JM , et al . Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial . Nat Med . 2025 ; 31 ( 12 ) : 4291 - 4300 .

Arisi MF , Dotan E , Fernandez SV . Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer . Int J Mol Sci . 2022 ; 23 ( 8 ): 4441 . Published 2022 Apr 18.

Crisafulli G . Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment . Genes (Basel) . 2025 ; 16 ( 1 ): 71 . Published 2025 Jan 9.

Liu Q , Li X , Jin T , Huo S , Su S , Liu N . Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization-Clinical Evidence and Challenges . Diagn Cytopathol . 2025 ; 53 ( 11 ) : 580 - 591 .

Han DM , Wakefield MR , Fang Y . Beyond Detection: Conventional and Emerging Biomarkers in Gastrointestinal Cancers . Cancers (Basel) . 2025 ; 17 ( 17 ): 2725 . Published 2025 Aug 22.

Ladabaum U , Mannalithara A , Weng Y , et al . Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy . Gastroenterology . 2024 ; 167 ( 2 ) : 378 - 391 .

Aziz Z , Wagner S , Agyekum A , et al . Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened . JAMA Netw Open . 2023 ; 6 ( 11 ): e2343392 . Published 2023 Nov 1.

Widman AJ , Shah M , Frydendahl A , et al . Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment . Nat Med . 2024 ; 30 ( 6 ) : 1655 - 1666 .

Landgren O , Prior TJ , Masterson T , et al . EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma . Blood . 2024 ; 144 ( 4 ) : 359 - 367 .

Pantel K , Alix-Panabieres C . Minimal residual disease as a target for liquid biopsy in patients with solid tumours . Nat Rev Clin Oncol . 2025 ; 22 ( 1 ) : 65 - 77 .

文章被引用时，请邮件提醒。

Submit

A Potential Marker for Neoplastic Proliferation and Treatment Response in Colorectal Cancer

Related Author

Mingxuan Li Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, United Kingdom

Related Institution

Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, United Kingdom

⁰